WallStreetZenWallStreetZen

AnalystsSalim Syed
Salim Syed's Stock Forecasts

Analyst Ranking
Bottom 13%
#4005 out of 4563 analysts
Average Return
-3.96%
Win Rate
28%13 out of 47
Risk vs Reward
Poor
Good

Salim Syed's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Nkarta IncNKTX
+260.30%$1.99$7.17
2023-08-14 -
2024-04-24
Strong Buy
Nkarta IncNKTX
+204.46%$2.36$7.17
2023-11-16 -
2024-04-24
Strong Buy
Bridgebio Pharma IncBBIO
+149.26%$11.47$28.59
2022-08-24 -
2023-08-23
Strong Buy
Bridgebio Pharma IncBBIO
+89.59%$35.17$66.68
2020-02-19 -
2021-02-19
Strong Buy
Bridgebio Pharma IncBBIO
+85.13%$13.52$25.03
2023-05-08 -
2024-04-24
Strong Buy

Salim Syed's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Enliven Therapeutics IncELVN
1Strong Buy$34.00+94.40%Initiates Coverage On
17 days ago
Nkarta IncNKTX
6Strong Buy$25.00+248.68%Maintains
a month ago
Wave Life Sciences LtdWVE
3Strong Buy$19.00+279.24%Maintains
a month ago
Vaxcyte IncPCVX
2Strong Buy$113.00+87.40%Maintains
a month ago
Cytokinetics IncCYTK
4Strong Buy$99.00+48.16%Maintains
2 months ago
Crispr Therapeutics AgCRSP
3Strong Buy$99.00+77.90%Maintains
2 months ago
Bridgebio Pharma IncBBIO
7Strong Buy$53.00+111.75%Maintains
2 months ago
Gilead Sciences IncGILD
4Strong Buy$90.00+34.17%Maintains
2 months ago
Biogen IncBIIB
11Strong Buy$277.00+37.14%Maintains
2 months ago
Atara Biotherapeutics IncATRA
3Hold$1.00+39.86%Downgrades
6 months ago
Amgen IncAMGN
4Hold$223.00-18.32%Maintains
8 months ago
Unity Biotechnology IncUBX
5Strong Buy$6.00N/AMaintains
a year ago
Coherus Biosciences IncCHRS
3Strong Buy$21.00N/AMaintains
a year ago
Assembly Biosciences IncASMB
1Strong Buy$36.00N/AMaintains
a year ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.